One additional blood clot for every 548 restrained patients
A large Danish study spanning two decades has found that psychiatric patients subjected to mechanical restraint face roughly twice the short-term risk of developing blood clots compared to those receiving chemical restraint. The finding arrives not as an indictment of a single practice, but as a reminder that even necessary interventions carry hidden costs — and that the most vulnerable patients often bear the heaviest burden of those costs. In a population already predisposed to vascular harm by illness, medication, and circumstance, immobility becomes one more weight on an already strained system.
- A twofold rise in blood clot risk within 30 days of mechanical restraint signals a measurable, if underappreciated, danger embedded in routine psychiatric care.
- Psychiatric patients already face elevated clot risk from their illnesses, medications, and sedentary lifestyles — mechanical restraint compounds a vulnerability that was never neutral to begin with.
- The absolute numbers remain low, but one additional blood clot for every 548 restrained patients represents a preventable harm at scale across thousands of hospitalizations each year.
- Researchers and editorialists are calling not for the abolition of restraint, but for sharper clinical awareness — earlier mobilization, closer monitoring, and a harder look at whether restraint is truly the last resort.
- The study's observational design leaves causation unproven, and gaps in baseline data on smoking and body weight mean the full picture is still coming into focus.
Danish researchers have identified a troubling pattern in psychiatric care: patients held in mechanical restraint — typically a waist belt, sometimes wrist or ankle straps — develop venous blood clots at nearly twice the rate of those managed with sedative medication instead. The study, published in The BMJ, drew on more than 24,000 psychiatric hospital admissions across Denmark between 2000 and 2022.
Among the roughly 10,200 patients exposed to mechanical restraint, 3.5 per 1,000 developed a blood clot within 30 days. In the chemical restraint group, that figure was 1.7 per 1,000 — a difference that translates to one additional case for every 548 restrained patients. The median patient age was 40, and about two-thirds were men.
The mechanism is not mysterious: immobility promotes clot formation, and mechanical restraint enforces immobility. What makes the finding significant is that psychiatric patients already carry elevated clot risk due to physical comorbidities, psychiatric medications, smoking, and inactivity. Restraint adds another layer of danger to an already vulnerable group.
The researchers adjusted for a wide range of confounding factors and drew from all Danish psychiatric hospitals, lending the findings considerable weight. Even so, this is observational work — unmeasured variables like body weight or smoking status could account for part of the association, and causation cannot be firmly established.
The absolute risk remains low, but the researchers and an accompanying editorial agree: this is a reducible harm. The study does not call for ending mechanical restraint, which remains sometimes necessary when patients pose immediate danger. It calls instead for using it more deliberately — with attention to early mobilization, closer monitoring for clot symptoms, and the possible role of preventive measures. The cost of restraint, it turns out, is not only measured in dignity.
Researchers in Denmark have found that when psychiatric hospital patients are held in mechanical restraint, their risk of developing blood clots nearly doubles within the following month. The study, published in The BMJ, examined more than 24,000 patients admitted to psychiatric hospitals across Denmark between 2000 and 2022, tracking outcomes for those subjected to either mechanical restraint—typically involving a waist belt, sometimes wrist or ankle straps—or chemical restraint through sedative medication.
The numbers are stark in their specificity. Among the roughly 10,200 patients exposed to mechanical restraint during the study period, 3.5 per 1,000 developed venous thromboembolism, a blood clot in the veins, within 30 days. In the comparison group receiving chemical restraint, the rate was 1.7 per 1,000. That twofold difference translates to one additional blood clot case for every 548 patients subjected to mechanical restraint. The median age of restrained patients was 40, and about two-thirds were men.
The mechanism is straightforward: mechanical restraint immobilizes patients, and immobility is a well-established risk factor for blood clots. But the finding matters because psychiatric patients already carry an elevated baseline risk. People with severe mental illness develop blood clots at higher rates than the general population, a phenomenon researchers attribute to a combination of factors—existing physical illnesses, medication effects, and lifestyle patterns including smoking and sedentary behavior. When restraint is added to that already-vulnerable population, the risk climbs further.
The researchers were careful to account for confounding variables. They adjusted their analysis for age, sex, marital status, education, admission diagnosis, medication history, and the timing between admission and restraint. They drew data from all Danish psychiatric hospitals, which strengthened their confidence in the findings. Still, this is observational research, not a controlled trial. The scientists cannot definitively prove that mechanical restraint causes the increased clot risk—unmeasured factors like smoking status or body weight could theoretically explain part of the association.
Yet the absolute risk, while doubled, remains low. The researchers emphasize this point: 3.5 cases per 1,000 patients is not a mass casualty scenario. But it is a preventable harm, or at least a reducible one. Mechanical restraint is sometimes necessary in psychiatric settings when patients pose immediate danger to themselves or others. The question becomes whether the clinical benefit of restraint justifies the added thromboembolism risk, and whether alternative approaches—or preventive measures like early mobilization or anticoagulation—might mitigate that risk.
The editorial accompanying the study notes that restraint may be a modifiable risk factor, but calls for more robust baseline data before firm clinical recommendations can be made. The Danish researchers themselves conclude that their findings underscore the importance of developing preventive strategies for patients who are restrained. The implication is clear: if mechanical restraint must be used, hospitals should consider what can be done to counteract its immobilizing effects—getting patients moving again as soon as safely possible, perhaps, or monitoring more closely for early signs of clot formation. The study does not argue for eliminating restraint altogether, but for using it more thoughtfully, with full awareness of what it costs.
Citações Notáveis
Mechanical restraint was associated with an elevated risk of blood clots. Although the absolute risk was low, these findings highlight the importance of preventive strategies to reduce the risk in patients exposed to mechanical restraint.— Danish researchers, published in The BMJ
A Conversa do Hearth Outra perspectiva sobre a história
Why does mechanical restraint specifically create this risk? Couldn't chemical restraint—sedation—also keep someone immobile?
It does, but the data shows chemical restraint doesn't carry the same elevated risk. The difference seems to be that sedation, while it does reduce movement, doesn't create the same degree of sustained physical constraint. Mechanical restraint is more absolute—the body is literally held in place.
So this is really a study about immobility and blood clots, with restraint as the vehicle.
Exactly. Immobility is the mechanism. But restraint is the policy lever. You can't easily change whether someone is immobile once they're sedated, but you can change how long someone stays in mechanical restraint, or what happens after.
The absolute risk is low—one extra case per 548 patients. Does that make this finding clinically meaningful?
It depends on your perspective. If you're one of those 548, it's very meaningful. But from a population standpoint, it's not a crisis. What matters is that it's preventable harm added to an already vulnerable group. Psychiatric patients already have higher baseline clot risk. This is an additional burden.
Can they prove restraint causes the clots, or is this just correlation?
They can't prove causation from this data alone. Other factors they didn't measure—smoking, weight, specific medications—could be playing a role. But they controlled for a lot of variables, and the signal is consistent across all Danish psychiatric hospitals. It's strong enough to warrant taking seriously.
What happens next? Do hospitals stop using restraint?
No. Restraint will still be used when patients are in immediate danger. But the study suggests hospitals should think about what comes after—how quickly can the patient be mobilized, are there preventive measures like blood thinners that make sense, is there closer monitoring for clot symptoms. It's about harm reduction, not elimination.